Analysts Set Gain Therapeutics, Inc. (NASDAQ:GANX) Price Target at $8.20

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has earned a consensus recommendation of "Buy" from the six analysts that are covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $8.20.

A number of research analysts have recently commented on GANX shares. HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Thursday, July 3rd. Chardan Capital restated a "buy" rating and issued a $6.00 target price on shares of Gain Therapeutics in a research note on Friday, March 28th.

Gain Therapeutics Trading Down 2.3%

Shares of GANX stock traded down $0.04 during trading hours on Thursday, reaching $1.73. The company's stock had a trading volume of 238,096 shares, compared to its average volume of 293,472. The stock has a market capitalization of $51.81 million, a P/E ratio of -2.01 and a beta of 0.12. Gain Therapeutics has a one year low of $0.89 and a one year high of $3.19. The firm's fifty day simple moving average is $1.83 and its 200 day simple moving average is $2.01. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.05.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.16) EPS for the quarter, meeting analysts' consensus estimates of ($0.16). Equities research analysts expect that Gain Therapeutics will post -1 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Bridgeway Capital Management LLC purchased a new position in Gain Therapeutics during the fourth quarter valued at $65,000. Kovitz Investment Group Partners LLC purchased a new position in Gain Therapeutics during the first quarter valued at $91,000. Northern Trust Corp raised its stake in Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company's stock valued at $183,000 after buying an additional 39,642 shares during the last quarter. Marshall Wace LLP purchased a new position in Gain Therapeutics during the fourth quarter valued at $198,000. Finally, Jones Financial Companies Lllp raised its stake in Gain Therapeutics by 83.6% during the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company's stock valued at $212,000 after buying an additional 44,750 shares during the last quarter. Hedge funds and other institutional investors own 11.97% of the company's stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.